Special precautions for disposal and other handling: Preparation: Irinotecan must be diluted prior to infusion in 5% Dextrose Injection, (preferred) or 0.9% Sodium Chloride Injection to a final concentration range of 0.12 to 2.8 mg/mL.
Handling: As with other potentially toxic anticancer agents, care should be exercised in the handling and preparation of infusion solutions prepared from irinotecan. The use of gloves is recommended. If irinotecan contacts the skin, wash the skin immediately and thoroughly with soap and water. If irinotecan contacts the mucous membranes, flush thoroughly with water.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Inspect vial contents for particulate matter and repeat inspection when drug product is withdrawn from vial into syringe.
Incompatibilities: Other drugs should not be added to the infusion solution.